Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. COHR

Go back to Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) Delayed: 26.40 -0.89 (3.26%)
Previous Close $27.29    52 Week High $42.49 
Open $27.43    52 Week Low $16.64 
Day High $27.43    P/E N/A 
Day Low $26.34    EPS $-0.42 
Volume 1,351,979       

NEWMARKET CORPORATION (NYSE: NEU) Delayed: 884.98 -6.89 (0.77%)
Previous Close $891.87    52 Week High $447.97 
Open $895.15    52 Week Low $322.54 
Day High $897.76    P/E 48.60 
Day Low $882.03    EPS $18.21 
Volume 117,996